Pfizer  3Q Revenues: $17.7 billion (+31%) 3Q Earnings: $4.5 billion (loss of $2.4 billion 3Q23)   YTD Revenues: $45.9 billion (+2%) YTD Earnings: $7.6 billion (+39%) Comments: Growth in the quarter was driven by revenues of $854 million from legacy Seagen, which was acquired in December of 2023; Vyndaqel family sales, up 63% operationally; Eliquis, up 9% operationally, Xtandi, up 28% operationally; and Nurtec ODT/Vydura globally, up 45% operationally. Growth was partially offset by lower re...